Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
AVBP
#2111
ArriVent BioPharma, Inc. Common Stock
22.9
7
+0.22%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
+0.22%
Monthly Change
-1.20%
6 month change
+19.57%
Cambio anual
-4.01%
Cierres anteriores
22.9
2
Open
22.9
3
Bid
Ask
Low
22.9
3
High
22.9
7
Volumen
76
Markets
Acciones
Atención Sanitaria
AVBP
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
Noticias
Cantor Fitzgerald, ArriVent hissesi için Ağırlık Artırma notunu yineledi
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald
Oppenheimer, ArriVent BioPharma hissesi için Outperform notunu yineledi
Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock
ArriVent BioPharma (AVBP): Its Leading Asset, Furmonertinib, Supports A Cautious Buy
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP)
Cantor Fitzgerald, ArriVent BioPharma hissesini Ağırlık Üstü tavsiyesiyle takibe aldı
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating
ArriVent, akciğer kanseri ilacı için önemli faz 3 çalışmasında ilk hastaya doz verdi
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug
BTIG, ArriVent BioPharma’ya onkoloji potansiyeli nedeniyle Al tavsiyesi verdi
ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential